• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Case presentation: the dancing man from sierra leone
Discussion Making this diagnosis is challenging, as brain imaging often shows non specific changes and blood results are usually normal. CSF may reveal raised proteins and WBCs. A high index of suspicion is required to arrange a brain biopsy as this confirms the diagnosis.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Al-Rifai, M. S., Salek-Haddadi, A. Tags: Immunology (including allergy), Neuroimaging, Stroke, Radiology, Drugs: musculoskeletal and joint diseases, Vascularitis, Surgical diagnostic tests ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

Intracranial Fibromuscular Dysplasia in a Middle-Aged Woman with Recurrent Ischemic Stroke (P4.388)
Conclusions: FMD is a rare disease and has very rarely been described in the intracranial arteries. This case illustrates the natural history and progression of FMD in this patient and elucidates the limited treatment options for preventing disease progression and secondary complications. FMD most predominantly affects younger to middle-aged females and if the disease process goes unrecognized it can have devastating consequences. It is important to continue research endeavors into the genetic and biologic determinants of FMD in order to develop better prevention and therapeutic strategies for this condition.Disclosure: Dr...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Beaton, N., Malik, A., Maque-Acosta, Y., Koch, S. Tags: Non-Atherosclerotic Arteriopathies Source Type: research

Clopidogrel-induced refractory thrombotic thrombocytopenic purpura successfully treated with rituximab
Publication date: Available online 2 December 2015 Source:Hematology/Oncology and Stem Cell Therapy Author(s): Sara Khodor, Miguel Castro, Colin McNamara, Chakra P. Chaulagain Thrombotic thrombocytopenic purpura (TTP) is a multisystem disorder characterized by microvascular aggregation of platelets and fibrin strands causing thrombocytopenia, microangiopathic hemolytic anemia, and organ dysfunction. TTP can develop as a result of a deficiency in ADAMTS13 enzyme activity due to either a genetic defect or, more commonly, the development of anti-ADAMTS13 autoantibodies. TTP can also be associated with pregnancy, organ t...
Source: Hematology Oncology and Stem Cell Therapy - March 7, 2016 Category: Cancer & Oncology Source Type: research